Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Fulcrum Therapeutics Inc (NQ: FULC ) 3.800 +0.140 (+3.83%) Streaming Delayed Price Updated: 12:47 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 156,590 Open 3.720 Bid (Size) 3.790 (4) Ask (Size) 3.800 (3) Prev. Close 3.660 Today's Range 3.685 - 3.840 52wk Range 2.865 - 13.70 Shares Outstanding 61,758,994 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 12 Health Care Stocks Moving In Thursday's Intraday Session September 26, 2024 Via Benzinga Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. September 26, 2024 Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. Via Investor's Business Daily Performance YTD -47.30% -47.30% 1 Month -53.09% -53.09% 3 Month -38.61% -38.61% 6 Month -57.82% -57.82% 1 Year -2.31% -2.31% More News Read More FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm! September 24, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm! September 16, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire Breaking Down Fulcrum Therapeutics: 7 Analysts Share Their Views September 13, 2024 Via Benzinga Wall Street's Top 10 Stock Calls This Week - Saturday, Sept. 14 September 14, 2024 Via Talk Markets Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 13, 2024 From Fulcrum Therapeutics, Inc. Via GlobeNewswire Dow Surges Over 100 Points; ModivCare Shares Plummet September 12, 2024 Via Benzinga Topics Stocks Exposures US Equities FULC Investors Have Opportunity to Join Fulcrum Therapeutics, Inc. Fraud Investigation with the Schall Law Firm September 12, 2024 From The Schall Law Firm Via Business Wire Crude Oil Surges 3%; Kroger Posts Upbeat Earnings September 12, 2024 Via Benzinga Exposures Fossil Fuels Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial September 12, 2024 Via Benzinga US Stocks Mixed; Producer Prices Increase In August September 12, 2024 Via Benzinga Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) September 12, 2024 From Fulcrum Therapeutics, Inc. Via GlobeNewswire Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease September 09, 2024 Via Benzinga Fulcrum Therapeutics to Participate in Upcoming September Conferences August 27, 2024 From Fulcrum Therapeutics, Inc. Via GlobeNewswire Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 23, 2024 From Fulcrum Therapeutics, Inc. Via GlobeNewswire Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer August 19, 2024 From Fulcrum Therapeutics, Inc. Via GlobeNewswire Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 09, 2024 From Fulcrum Therapeutics, Inc. Via GlobeNewswire 8 Health Care Stocks With Whale Alerts In Today's Session August 01, 2024 Via Benzinga Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024 July 31, 2024 From Fulcrum Therapeutics, Inc. Via GlobeNewswire Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET July 24, 2024 From Fulcrum Therapeutics, Inc. Via GlobeNewswire Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter July 16, 2024 Via Benzinga Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress June 12, 2024 From Fulcrum Therapeutics, Inc. Via GlobeNewswire 10 Health Care Stocks With Whale Alerts In Today's Session June 11, 2024 Via Benzinga Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference June 06, 2024 From Fulcrum Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
